Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
At Epizyme, CEO Gould steps aside and Bazemore takes the reins |
|||||||||||||||||||
Epizyme ($EPZM) CEO Robert Gould announced this week that he'll step down next month after more than 5 years leading the company. Through the transition, he'll keep a seat on the company's board as it presses forward with two promising blood cancer drugs. Robert Bazemore, former chief operating officer at Synageva until it was purchased by Alexion ($ALXN), will take the reins. At Synageva, Bazemore was responsible for establishing the company's global commercial and medical organization for the company's first launch and managing the company's transition into a commercial enterprise. Before Synageva, Bazemore spent 12 years at several Johnson & Johnson ($JNJ) operations and before that 11 years at Merck ($MRK). "I am thrilled to welcome Rob Bazemore as our next CEO. I am pleased to have achieved much of what I set out to do when I became Epizyme's CEO, and I look forward to supporting the company through this transition and its future growth as I return to my role as a director on the board," Gould said. Release
|